ScholarIQanswers from OpenAlex & ORCID
Stephen C. Rubin
ResearcherPublications, citations & collaboration network
Stephen C. Rubin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stephen C. Rubin have?
ScholarIQindexed works
Stephen C. Rubin has 398 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stephen C. Rubin have?
ScholarIQcitation count
Stephen C. Rubin has 21,417 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stephen C. Rubin?
ScholarIQh-index
Stephen C. Rubin has an h-index of 71 in OpenAlex.
What is the i10-index of Stephen C. Rubin?
ScholarIQi10-index
Stephen C. Rubin has an i10-index of 213 in OpenAlex.
What is the ORCID of Stephen C. Rubin?
ScholarIQorcid
The ORCID for Stephen C. Rubin is on the source record.
What is the OpenAlex record for Stephen C. Rubin?
ScholarIQopenalex
The OpenAlex for Stephen C. Rubin is on the source record.
What are the most-cited papers on Stephen C. Rubin?
ScholarIQmost cited works
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel
Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
William E. Winter, G. Larry Maxwell, Chunqiao Tian, Michael J. Sundborg, G. Scott Rose, Peter G. Rose, Stephen C. Rubin, Franco M. Muggia, William P. McGuire
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
Peter G. Rose, Stacy Nerenstone, Mark F. Brady, Daniel L. Clarke‐Pearson, George J. Olt, Stephen C. Rubin, David H. Moore, James M. Small
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O’Malley, Matthew Boente, Helen Michael, Bradley J. Monk
Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer
Tina R. Norton, Sharon L. Manne, Stephen C. Rubin, John Carlson, Enrique Hernández, Mitchell I. Edelson, Norman D. Rosenblum, David Warshal, Cynthia Bergman